New Zealand - English - Medsafe (Medicines Safety Authority)

aurobindo pharma nz limited - carvedilol 12.5mg - film coated tablet - 12.5 mg - active: carvedilol 12.5mg excipient: colloidal silicon dioxide crospovidone hypromellose lactose monohydrate macrogol 400 magnesium stearate polysorbate 80 povidone purified water   sucrose titanium dioxide - indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - carvedilol 12.5mg;   - film coated tablet - 12.5 mg - active: carvedilol 12.5mg   excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate microcrystalline cellulose opadry white ys-22-18096 povidone - hypertension dp-carvedilol is indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (eg calcium channel blockers, diuretics).

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - carvedilol 12.5mg;   - tablet - 12.5 mg - active: carvedilol 12.5mg   excipient: colloidal silicon dioxide crospovidone iron oxide red iron oxide yellow lactose monohydrate magnesium stearate microcrystalline cellulose povidone - carvedilol sandoz is indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - carvedilol - oral tablet - 12.5mg

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - carvedilol 12.5mg - tablet - 12.5 mg - active: carvedilol 12.5mg excipient: croscarmellose sodium hyetellose lactose monohydrate macrogol 8000 magnesium stearate microcrystalline cellulose titanium dioxide - apo-carvedilol is indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 12.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; magnesium stearate; crospovidone; microcrystalline cellulose; povidone; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

United States - English - NLM (National Library of Medicine)

cipla usa inc. - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg - carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ace inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see drug interactions (7.4), clinical studies (14.1)] . carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see clinical studies (14.2)] . carvedilol tablets are indicated for the management of essential hypertension [see clinical studies (14.3, 14.4)] . it can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see drug interactions (7.2)] . carvedilol is contraindicated in the following conditions: - bronchial asthma or related bronchospastic conditions. deaths from status

New Zealand - English - Medsafe (Medicines Safety Authority)

norton healthcare limited (nz) - carvedilol 12.5mg;  ;   - tablet - 12.5 mg - active: carvedilol 12.5mg     excipient: colloidal silicon dioxide crospovidone iron oxide red lactose monohydrate magnesium stearate povidone - carvedilol tablets are indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (eg calcium channel blockers, diuretics).

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - carvedilol, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; microcrystalline cellulose; crospovidone; colloidal anhydrous silica; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - carvedilol is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii to iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Malta - English - Medicines Authority

aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - carvedilol - film-coated tablet - carvedilol 12.5 mg - beta blocking agents